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Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patients do
relapse and survival following relapse is poor. Altered DNA methylation is highly prevalent in ALL and raises the
possibility that DNA methylation-based biomarkers could predict patient outcome. In this study, genome-wide
methylation analysis, using the Illumina Inﬁnium HumanMethylation450 BeadChip platform, was carried out on 52
diagnostic patient samples from 4 genetic subtypes [ETV6-RUNX1, high hyperdiploidy (HeH), TCF3-PBX1 and dic(9;20)
(p11–13;q11)] in a 1:1 case-control design with patients who went on to relapse (as cases) and patients achieving long-
term remission (as controls). Pyrosequencing assays for selected loci were used to conﬁrm the array-generated data.
Non-negative matrix factorization consensus clustering readily clustered samples according to genetic subgroups and
gene enrichment pathway analysis suggested that this is in part driven by epigenetic disruption of subtype speciﬁc
signaling pathways. Multiple bioinformatics approaches (including bump hunting and individual locus analysis) were
used to identify CpG sites or regions associated with outcome. However, no associations with relapse were identiﬁed.
Our data revealed that ETV6-RUNX1 and dic(9;20) subtypes were mostly associated with hypermethylation; conversely,
TCF3-PBX1 and HeH were associated with hypomethylation. We observed signiﬁcant enrichment of the neuroactive
ligand-receptor interaction pathway in TCF3-PBX1 as well as an enrichment of genes involved in immunity and infection
pathways in ETV6-RUNX1 subtype. Taken together, our results suggest that altered DNA methylation may have
differential impacts in distinct ALL genetic subtypes.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common
form of childhood cancer, representing more than 80% of
diagnosed childhood leukemia cases in the UK each year,
with a gradually increasing incidence.1 It has long been estab-
lished that chromosomal abnormalities are major drivers of
ALL. Current treatment involves risk stratification guided by
age and white blood cell count (WBC), karyotype, and treat-
ment response.2,3 Although risk stratification and multi-agent
chemotherapy have achieved around 90% survival, about
10% of patients relapse.2 Increasing evidence supports the
inclusion of additional genomic signatures generated by tran-
scriptome, as well as copy number changes and mutations in
risk stratification.4-6 Current efforts are focused on identify-
ing biomarkers for predicting relapse or reducing late compli-
cations of intensified therapy.
DNA methylation is a key epigenetic modification, which
occurs primarily at CpG dinucleotide sequences.7 CpG sites are
underrepresented throughout the genome, with the exception of
short stretches of DNA known as CpG islands, which are often
associated with gene promoter regions.8 The development of can-
cer, including ALL, is associated with dramatic shifts in genomic
DNA methylation, involving both genome wide hypomethylation
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and localized hypermethylation of promoter-associated CpG
islands.9 Hypermethylation of promoter-associated CpG islands
leads to gene inactivation and many important tumor suppressor
genes are known to be inactivated by this mechanism.10 Further-
more, the comparative ease of detection and tumor specificity of
CpG island hypermethylation has led to considerable interest in
their potential as novel prognostic biomarkers.11 Such methylation
based markers may help direct current therapies, such as methyla-
tion of the DNA repair gene, MGMT, which predicts response to
therapy in glioblastoma patients,12 or improve patient stratifica-
tion, as we have demonstrated in chronic lymphocytic leukemia.13
While our understanding of methylation in cancer is improv-
ing, little is known about the role of methylation changes in the
development and progression of childhood ALL. However, a
number of studies have provided preliminary evidence that
altered patterns of DNA methylation may be associated with out-
come in ALL.14-19 Recent advances in whole genome screening
technologies have facilitated the screening of CpG sites at a geno-
mic level, generating a more thorough view of the methylation
landscape15,20-23 and raised the possibility of using such technol-
ogies to identify methylation based biomarkers that could be
used to further improve risk stratification in ALL patients.
In the present study we applied Illumina Infinium Human-
Methylation450 genome-wide methylation arrays that cover
> 485,000 methylation sites, including 99% of Refseq genes as
well as 96% of CpG islands24 to a cohort of 52 diagnostic ALL
samples in a 1:1 case-control design (26 cases who subsequently
relapsed and 26 controls in continuous remission) to identify
novel CpG sites that may be associated with relapse in 4 major
cytogenetic subgroups in BCP-ALL.
Results
Genome-wide patterns of DNA methylation are strongly
associated with cytogenetic subgroups
Genome-wide methylation data derived from the Infinium
HumanMethylation450 BeadChip arrays was compared across
the 52 diagnostic ALL samples and compared with control nor-
mal cells (B lymphocytes (CD19) and monocytes (CD14)
derived from healthy volunteers). The majority of samples
(n D 40) were derived from the 2 most common cytogenetic sub-
types (ETV6-RUNX1, n D 20 ; HeH, n D 20), which despite
having a good outcome still account for »40% of relapse cases
due to their prevalence (Moorman et al. 2010). Additional sam-
ples from less common cytogenetic subtypes [TCF3-PBX1,
n D 6; dic(9;20)(p11–13;q11), n D 6] were also included to
determine if any relapse-associated methylation changes were
independent of genetic subgroup and also to allow clearer defini-
tion of subgroup specificity of DNA methylation in childhood
ALL. Non-negative matrix factorization (NMF) was used to
reduce the dimensionality of the data from 10,000 probes to a
few metagenes. For each factorization rank from 3 to 7, we
assessed stability of factorization by cophenetic coefficient
(Fig. S1) and silhouette scores of consensus subgroup assign-
ments after 100 iterations (Fig. 1A). NMF separated the samples
into 4 groups which corresponded very closely to the subgroups
(Fig. 1), with only a single HeH sample and a single dic(9;20)
sample failing to cluster with their genetic counterparts (we have
excluded the possibility of cryptic TCF-PBX1 translocation via
interphase FISH). The identified subgroups are characterized by
a positive silhouette score (Fig. 1B), indicative of samples being
placed into the correct cluster, and show clear separation by prin-
cipal component analysis (PCA) of the methylation data
(Fig. 1C). This association with cytogenetic subtype is consistent
with previous reports.15,20-23 The differentially methylated CpG
sites that demonstrated subtype specificity are listed for each sub-
type in supplementary Table 1. Furthermore, there were clear
differences in the genomic locations and directionality of methyl-
ation changes between the subtypes; for example, the ETV6-
RUNX1 and dic(9;20) subtypes exhibited relatively more hyper-
methylation than hypomethylation, while changes in the HeH
and TCF3-PBX1 subtypes were predominantly hypomethylated
(Fig. S2). We have performed a gene enrichment pathway analy-
sis of these subtype specific differentially methylated cytosines
(DMCs) after correcting for probe distribution and multiple test-
ing in KEGG database. Interestingly, this analysis identified 10
pathways that were significantly over-represented in the ETV6-
RUNX1 DMCs (after correction for multiple testing) and 8/10
of these pathways were related to immune function. While no
pathways were identified as over-represented in the HeH and dic
(9;20) subtypes, a highly significant association (P D 5.7 £
10¡17, after correction) was found with neuroactive ligand-recep-
tor interaction in the TCF3-PBX1 subtype (online supplementary
Table 2). The association between subtype specific DMCs and
specific pathways further implicates the differential methylation
in different biological behavior of the cytogenetic subtypes.
All samples in the cohort had also previously been analyzed
using Multiplex Ligation-dependent Probe Amplification
(MLPA)25 to identify copy number alterations in genes with a
known role in ALL development (Fig. 2A). It is possible that the
complexity of data derived from the HumanMethylation450
BeadChip arrays was masking changes at such key leukemia asso-
ciated genes or that DNA methylation changes may be acting as
a second hit at sites of heterozygous deletions. Therefore, methyl-
ation at all CpG sites associated with the 8 loci (CRLF2, IL3RA,
and CSF2RA, considered as PAR1 locus) covered by the MLPA
analysis were extracted from the array data. As illustrated for
PAX5 in Figure 2B, methylation levels were similar across the
sample set. Raw methylation data could also be used to assess
potential changes in copy number.26 This analysis confirmed the
MLPA data showing PAX5 deletions in 5 of the patients
(Fig. S3). However, methylation of PAX5 did not vary in the
samples with confirmed deletions (Fig. 2B), suggesting that
altered methylation was not functioning as a second hit, at least
for PAX5.
Genome-wide patterns of DNA methylation are not
significantly different in patients that subsequently relapsed
The development of relapse is a crucial determinant of out-
come, as survival rates following relapse are much lower. Identifi-
cation of patients at the time of diagnosis who will subsequently
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relapse and, indeed, those unlikely to relapse, is extremely valu-
able to optimize their treatment. Consequently, genome-wide
methylation data was analyzed, using a number of different
methods, to attempt to discover methylation-based signatures in
diagnostic samples that were predictive of subsequent relapse.
As described above, unsupervised NMF consensus clustering sep-
arated the samples by underlying genetic subgroups (Fig. 1).
However, within each subgroup, there was no evidence of cluster-
ing of samples based on eventual outcome. In case the strong
association with cytogenetics was masking a relapse signature,
this analysis was repeated following the removal of data from the
probes that were differentially methylated between subgroups;
however, this analysis also showed no evidence of clustering
according to outcome and no individual CpG site exhibited a sta-
tistically significant correlation with outcome (data not shown).
Furthermore, analysis of individual CpG sites [differential CpG
sites were classed as having a difference in mean b value > 0.2
and an adjusted P-value < 0.01 (Nordlund-Backlin et al. 2013)]
did not identify any individual CpG sites that was significantly
associated with relapse. Genetic subtype specific analysis, for the
ETV6-RUNX1 and HeH subgroups, also yielded no individual
probes significantly associated with subsequent relapse.
Altered DNA methylation often occurs coordinately across
genomic regions, such as CpG islands. To determine whether
any such regions were differentially methylated between sam-
ples from patients who subsequently relapsed and those who
did not, a bump-hunting algorithm27 within the Bumphunter
package was utilized, with 1000 permutations. Probes were
clustered into a region based on distance: all differentially
methylated probes that were located within 300 bp of another
differentially methylated probe were placed into the same clus-
ter group, so that window widths were flexible and defined by
Figure 1. Methylation patterns identify cytogenetic groups in BCP-ALL. (A) Consensus clustering of DNA methylation patterns in 52 BCP-ALL samples.
NMF using standard methods was carried out over 100 runs for 3–6 metagenes, with the cophenetic coefﬁcient supporting 4 groups (metagenes). Col-
ored squares above each column indicate the cytogenetic subgroup for each samples, showing the single ETV6-RUNX1 samples and single dic(9;20) sam-
ple that clustered with the TCF3-PBX1 group (group 1). (B) Silhouette plot by sample type and cytogenetic groups. Silhouette plots of consensus NMF
subgroups demonstrate close relationships between cytogenetic subgroup and methylation subgroup assignment. For each subgroup, the number of
members, the percentage of cluster members and average silhouette (si) width are shown. Samples marked with an asterisk indicate outlier cytogenetic
cases that do not cluster with patients of the same cytogenetic subtype. (C) Principal component analysis based on 10000 most variable DMCs, labeled
by methylation subtype. The ﬁrst 3 principal component scores are shown for each sample. For each group, covariance spheroids, colored by the pre-
dominating cytogenetic subgroup, are plotted along the 95% conﬁdence intervals.
www.tandfonline.com 719Epigenetics
proximity and number of differentially methylated probes,
rather than by fixed size. P-values were also adjusted to control
the false discovery rate (FDR) using the Benjamini–Hochberg
method. However, neither approach identified regions in
which the levels of methylation were significantly different
between samples from the 2 different outcome categories at
5% FDR and 10% family-wise error rate (FWER), when all
samples were analyzed simultaneously (Table 1). This was also
largely true when the HeH and ETV6-RUNX1 groups were
analyzed separately, although a weak association was found at
the EXT1 loci specifically in the HeH subgroup (Table 1).
Genetic subtype specific analysis was again restricted to ETV6-
RUNX1 and HeH subgroups. Single gene analysis utilizing
pyrosequencing validated the array-generated data at the EXT1
locus; however, expansion of the analysis to additional
diagnostic samples did not support an association between
EXT1 methylation and subsequent relapse (Fig. S4).
A recent study by Nordlund et al.20 reported genome-wide
methylation patterns for multiple childhood ALL cytogenetic
subgroups, including the 4 included in this study. Similar to the
results reported above, they also identified large-scale differences
in DNA methylation between different cytogenetic subgroups.
To assess the reproducibility of the genetic subgroup-specific
methylation profiles identified by Nordlund et al., we deter-
mined whether the CpG marker sets identified as specific for
individual cytogenetic subgroups in that study would also iden-
tify individual cytogenetic subgroups in our data set. As shown in
Figure 3, all 4 cytogenetic subgroups were identified using their
markers sets [with 54.0% (1141 / 2114), 37.7% (1136 / 3014),
28.3% (314 / 1110), 14.9% (353 / 2370) subtype specific CpG
A
B
Figure 2. (A) Demographic and clinical features of 52 diagnostic bone marrow samples. Abbreviations: WBC, white blood cell; NCI risk, national cancer
institute risk; SR, standard risk; HR, hazard ratio; HeH, High hyperdiploidy. Some of the gene aberrations listed are linked to the primary genetic aberra-
tions (i.e., CDKN2A/B and PAX5 in dic(9;20), rather than true focal aberrations). Similarly, gene abberations resulting from whole chromsome gain (HeH) or
loss have not been shown. (B) Deletion of PAX5 was observed in 5 patients via MLPA shown in pink blocks above. We clustered the data by looking at
methylation probes 5 kb upstream and downstream of PAX5. The result shows that deletion status of PAX5 does not seem to correlate with methylation
values and seems independent of copy number.
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markers concordant with our analysis for ETV6-RUNX1, HeH,
TCF3-PBX1, and dic(9;20) respectively, using the same criteria
for defining subtype specific methylated loci].20
Nordlund et al. also identified a set of 90 DMCs associated
with relapse, specifically in ETV6-RUNX1 positive cases. To vali-
date this marker set for the identification of subsequent relapse,
we applied these 90 relapse predicting DMCs to our datasets.
However, as shown in Figure 3E, unsupervised clustering using
the same 90 CpG sites, did not appear to differentiate between
relapse and non-relapse samples (specifically in ETV6-RUNX1
positive cases). To determine whether single CpG sites from
within this group of 90 sites were associated with relapse, each
locus was assessed individually in our ETV6-RUNX1 positive
sample set. However, only one of the 90 loci exhibited a statisti-
cally significant association with subsequent relapse in our sample
set (cg17033047 within the KCNA3 locus, P D 0.01, uncor-
rected P-value, higher methylation levels in relapse samples).
Expanding the analysis for this site to an additional 57 ETV6-
RUNX1 positive cases (of which 3 relapsed) failed to confirm the
differential methylation seen in the 20 samples used for the array
analysis (Fig. S4D). As the size of the ETV6-RUNX1 positive
sample set was small (n D 20) with only 10 relapsed ETV6-
RUNX1 cases, the possibility cannot be ruled out that weak corre-
lations may be detectable in larger sample sets. However, it
should also be noted that our data set had more relapsed ETV6-
RUNX1 cases than Nordlund et al.20 Taken together, these
results suggest that DNA methylation at these loci is unlikely to
be of significant clinical utility for the prediction of relapse in
ETV6-RUNX1 positive childhood ALL.
Discussion
Alterations in DNA methylation are highly prevalent in child-
hood ALL, suggesting that they may have a major impact on the
biology and clinical behavior of the disease, as well as raising the
Table 1. Differentially methylated regions identiﬁed by Bump Hunter analysis
All samples
Chr Start End No. of CpG sites P-value FWER1 Width (bps) Nearest Gene Distance to TSS2
chr10 134765033 134765099 3 0.00029 0.354 67 TTC40 ¡8944
chr8 119124051 119124311 4 0.00049 0.443 261 EXT1 0
chr21 38468606 38468606 1 0.00042 0.750 1 TTC3 10516
chr2 77235218 77235218 1 0.00066 0.883 1 LRRTM4 514284
chr10 675888 675937 3 0.00242 0.887 50 DIP2C 59671
chr17 68164468 68164468 1 0.00093 0.934 1 KCNJ2-AS1 1075
chr9 124022933 124022933 1 0.00101 0.942 1 GSN 59172
chr3 168308798 168308798 1 0.00118 0.962 1 EGFEM1P 59276
chr6 32774788 32774788 1 0.00121 0.963 1 HLA-DOB 10037
chr1 248020692 248021091 4 0.00483 0.971 400 TRIM58 191
chr10 134765033 134765099 3 0.00029 0.354 67 TTC40 ¡8944
ETV6-RUNX1
Chr Start End No. of CpG sites P-value FWER Width (bps) Nearest Gene Distance to TSS
chr5 158086454 158086454 1 1.64E-05 0.063 1 EBF1 437160
chr15 69744390 69744684 4 7.88E-05 0.236 295 RPLP1 ¡475
chr8 1651128 1651128 1 7.30E-05 0.242 1 DLGAP2 201596
chr4 134069593 134070441 10 0.00015 0.404 849 PCDH10 ¡29
chr5 178986620 178986906 5 0.00037 0.670 287 RUFY1 0
chr11 100760935 100760935 1 0.00031 0.693 1 ARHGAP42 202528
chr6 160023581 160024144 6 0.0009 0.898 564 SOD2 90209
chr21 46077454 46077731 6 0.0011 0.924 278 TSPEAR 53764
chr14 76015669 76015669 1 0.00079 0.946 1 BATF 26885
chr10 124639132 124639260 7 0.00135 0.952 129 FAM24B 0
HeH
Chr Start End No. of CpG sites P-value FWER Width (bps) Nearest Gene Distance to TSS
chr8 119124051 119124462 5 1.58E-06 0.006 412 EXT1 0
chr10 675888 675937 3 0.00019 0.380 50 DIP2C 59671
chr16 66458043 66458043 1 0.00021 0.560 1 BEAN1 ¡3157
chr4 99850801 99851281 9 0.00047 0.625 481 EIF4E 505
chr22 25201958 25202163 6 0.00053 0.664 206 SGSM1 0
chr17 76875678 76876239 4 0.00055 0.669 562 TIMP2 42244
chr10 113944114 113944114 1 0.00031 0.695 1 GPAM ¡577
chr5 150284600 150284796 2 0.00065 0.786 197 ZNF300 ¡55
chr1 248020377 248021091 8 0.00083 0.802 715 TRIM58 0
chr8 19459672 19460243 4 0.00089 0.807 572 CSGALNACT1 0
chr8 119124051 119124462 5 1.58E-06 0.006 412 EXT1 0
1
P-Value corrected for family-wise error rate, with B D 1000 permutations.
2Transcriptional start site.
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Figure 3. Principal component analysis of subtype-speciﬁc DMCs identiﬁed by Nordlund et al. recapitulates genetic subgroup separation and validates
them as biomarkers for these subgroups. For each plot, 2 covariance spheroids have been plotted along the 95% conﬁdence intervals for (A) dic(9;20)
and others; (B) TCF3-PBX1 and others; (C) ETV6-RUNX1 and others; (D) HeH and others. Individual samples are colored by their cytogenetic status; TCF3-
PBX1 cases are shown red, ETV6-RUNX1 in orange, dic(9;20) in blue and HeH in purple. (E) Previously reported relapse-associated DMCs in ETV6-RUNX1
positive cases are not recapitulated in our data set. The color bar at the top of the heatmap indicates sample type; continuous remission and subse-
quently relapsing patients are shown gray and black respectively. The heatmap shows the methylation status for 90 relapse-associated probes identiﬁed
by Nordlund et al.20 Samples (columns) and probes (rows) were clustered using complete linkage and Euclidean distance. Fully methylated probes are
shown dark red, unmethylated probes shown dark blue and hemi-methylated probes are shown in white.
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possibility that differences in DNA methylation patterns at diag-
nosis may be useful biomarkers for prediction of clinical out-
come. In this study, genome-wide methylation analysis was
carried out on 52 diagnostic ALL samples from 4 cytogenetic
subgroups, in which 50% of patients subsequently relapsed and
50% remained in long-term remission. NMF consensus cluster-
ing identified multiple sub-groups within the methylation data;
however, these were related to the underlying genetic differences
and did not differentiate between samples with different relapse
status. Different bioinformatics approaches were undertaken in
an attempt to identify a single or a small number of methylation
variable sites that could identify at diagnosis those patients most
likely to relapse. However, none of these approaches identified
any loci whose methylation status was significantly associated
with subsequent relapse. Some limited evidence for an association
with relapse was found at sites within the EXT1 and KCNA3 loci
in the array data; however, neither were confirmed by pyrose-
quencing analysis of additional samples. The results presented
here, in combination with previously published data,20 suggest
that genome-wide methylation profiles, identified using the
Infinium HumanMethylation450 BeadChip array platform, may
be unlikely to yield clinically useful biomarkers for prediction of
relapse in childhood ALL over and above the prognostic informa-
tion already provided by cytogenetic subgroups.
However, there was a clear correlation between genome-
wide patterns of DNA methylation and the different cyto-
genetic subgroups, consistent with previous studies.15,20-23 In
addition, we were able to use the marker sets recently identi-
fied by Nordlund et al.,20 whose analysis utilized the same
array platform, on our data set and validate their cytogenetic
specific markers. Thus, while DNA methylation profiles did
not appear to augment the prognostic information provided
by standard cytogenetics, the consistency of the methylation
changes in relation to cytogenetic subgroups suggests that
these altered patterns of DNA methylation may be an impor-
tant determinant of their different clinical behavior. Further-
more, the results suggest that genomic DNA methylation
could be used as a surrogate for cytogenetic analysis in cases
where genomic DNA, but no intact cells, was available.
While methylation profiles associated with cytogenetic sub-
groups could be validated, the marker set suggested to predict
outcome in ETV6-RUNX1 positive cases did not validate in
our data set. A potential cause would be that the patients were
treated on different protocols, although the treatment proto-
cols used were highly similar.28,29 In addition, the patient
populations were derived from different geographical loca-
tions, so differences in genetic background may have also
played a role. However, the results do indicate that the identi-
fied methylation profile is not readily portable to other patient
populations.
Although the cytogenetic subtypes showed a clear correlation
with methylation profiles, the data presented here and previously
published20,23 showed that this clustering was not absolute. For
example, in the data set presented here, one dic(9;20) and one
HeH case clustered with the TCF3-PBX1 samples. In such cases,
it is not clear whether the risk of relapse in the patients would
reflect their cytogenetic subgroup or be equivalent to the sub-
group defined by the methylation profile. However, the compara-
tive rarity of these cases (only 2/52 samples in this study) meant
that a much larger study would be required to have sufficient
power to address the potential prognostic significance of such
“outlier” samples.
While analysis of DNA methylation profiles has identified
subtype specific methylation changes, it is important to note that
many of the alterations identified in this and other studies are
shared across cytogenetic subgroups. This implies that a large set
of epigenetic changes are either a prerequisite for, or an inevitable
consequence of, the development of ALL. In general, the consis-
tency of alterations seen in ALL and indeed other tumors has led
to the hypothesis that cancer, in many instances, may be initiated
specifically from a set of cells that have already undergone exten-
sive epigenetic changes.30 Thus, analysis of the targets for altered
DNA methylation that are conserved across all ALL subtypes
may be able to identify key drivers of the disease that could be
targets for the development of novel therapeutic approaches.
The cytogenetic subtype specificity of many of the methyla-
tion changes suggests that these differential methylation patterns
may be important in the different biological/clinical behavior of
the different cytogenetic groups. Here we used gene enrichment
pathway analysis to investigate whether subtype specific DMCs
might be preferentially targeting specific biological pathways.
Our observation of gene enrichment pathways in ETV6-RUNX1
involving immunity and infection pathways (8/10 pathways with
a significant association are related to immune function) is a
potentially exciting avenue for future analysis, as it may relate to
previous reports that have suggested abnormal immune response
as a major factor shaping the trajectory of leukemogenesis.31,32
In the TCF3-PBX1 subtype, we identified a remarkable enrich-
ment for genes in the neuroactive ligand-receptor interaction
pathway. Interestingly, a large fraction of these methylation
changes map to gene promoter regions, suggesting that they are
likely to be associated with functional changes in gene expression.
Previous reports have shown that neuroactive ligand-receptor
interaction pathways are associated with acute leukemias as well
as several other diseases33,34 Further investigation of the potential
role of this pathway in TCF3-PBX1 driven leukemia would be
warranted. Integrating the methylation data with gene expression
data would help clarify whether the subtype specific patterns of
methylation correlate with clear differences in subtype specific
gene expression and thus potentially with downstream gene
function.
This study focused specifically on DNA methylation. To
more clearly understand the epigenome of pediatric ALL it may
be necessary to undertake integrative studies assessing other epi-
genetic mechanisms, such as nucleosome remodeling and histone
modifications, as well as associations with microRNA and gene
expression in the same sample sets. In addition, while the Infin-
ium HumanMethylation450 BeadChip array platform used in
this and other studies20 has coverage of much of the genome,
including 99% of RefSeq genes, it only contains probes for about
2% of the total number of CpG sites in the human genome.
Some studies have used whole-genome bisulfite sequencing in an
www.tandfonline.com 723Epigenetics
attempt to address this limitation. However, at this time, it is
challenging to apply this approach to more than just a small
number of samples due to cost and increased DNA require-
ment.35-37. Thus, further technical developments in genome-
wide bisulfite sequencing and integration with other epigenetic
mechanisms will be required to allow the identification of a com-
plete picture of the epigenetic changes in childhood ALL and
how this relates to changes in gene expression profiles. Such inte-
grative studies may reveal biologically relevant epigenetic
changes.
Materials and Methods
Patients and sorted cells
Bone marrow samples from 52 pediatric patients with ETV6-
RUNX1 (n D 20), high hyperdiploidy (51–65 chromosomes)
(HeH) (n D 20), TCF3-PBX1 (n D 6) and dic(9;20)(p11–13;
q11) (n D 6) who consented to be enrolled on the ethically-
approved UK ALL treatment trial, ALL97/99. All samples used
had a high blast count (average 93%). An additional 123 diag-
nostic bone marrow samples from MRC ALL97/99 (HeH,
n D 66 and ETV6-RUNX1, n D 57) were used in confirmatory
pyrosequencing analysis.
MLPA
Genomic DNA from patient bone marrow aspirates was
extracted using standard procedures. Genomic DNA from
healthy donors was obtained for use as control samples. DNA
was analyzed using the SALSA MLPA Kit P335 (MRC Holland,
Amsterdam, The Netherlands), as described previously.25 This
kit includes probes for IKZF1 (8 probes), CDKN2A/B (3 probes),
PAX5 (6 probes), EBF1 (4 probes), ETV6 (6 probes), BTG1
(4 probes), RB1 (5 probes), and the PAR1 region: CRLF2,
CSF2RA, and IL3RA (one probe each). Data were analyzed using
GeneMarker V1.85 analysis software (SoftGenetics). All loci
were found to be deleted in at least one patient and the majority
of patients (40/52) had deletion of one or more of the genes
assessed.
Bisulfite conversion and 450K array hybridization
Bisulfite conversion was performed using the Zymo EZ-96
DNA methylation kit and the bisulfite converted DNA was
hybridized to the HumanMethylation450 Analysis BeadChip
(Illumina) and processed following the 450K methylation array
procedure, according to manufacturer’s instructions. Hybridiza-
tion fluorescent signals were read by the Illumina BeadStation
GX scanner. This procedure was performed at Wellcome Trust
Clinical Research Facility, Edinburgh, UK.
Bioinformatics analyses
The arrays report DNA methylation status (b value) at
> 485,000 CpG loci. The b value can range from 0 to 1,
representing fully unmethylated and methylated values. Array
processing, normalization and quality control checks, as well
as derivation of the b values from the raw intensity values
(.idat files), were implemented using the R package ‘minfi’.38
We employed conservative quality control measures to filter out
poorly performing and potentially confounding loci. Briefly, a
filtering process removed unannotated probes (i.e., not mapped
to the genome), probes located on chromosomes X/Y, probes
that aligned to more than one place in the genome, allowing for
1 mismatch, and probes that had a SNP with a minor allele fre-
quency of 5% or greater within 50 bp of the interrogated site.
Probes that failed in >5% of samples were also removed.39-42
The remaining probe b values (429,750) were converted to M-
scores,43 and the top 10,000 most variable probes by standard
deviation were selected for subgroup identification. The 10,000
most variable probes were used for the clustering as this is
equivalent to the inflection point in the curve (when mapping
variability versus probe number), such that probes that were
excluded were largely non-variable and would have added little
to the clustering. A non-negative matrix factorization (NMF),44
based consensus clustering approach was performed using the R
package NMF.45 An optimal factor number (i.e., subgroup
number) was selected by maximizing cluster number while
maintaining cophenetic correlation coefficient. Cluster stability
measures (silhouette scores) were used to assess the quality of
the identified subgroups. Pathway enrichment analysis was per-
formed using ‘GOseq’ bioconductor package using the KEGG
database. P-values were calculated by using both resampling and
the Wallenius approximation based methods available in
GOseq.46 P-values were also adjusted to control the false discov-
ery rate (FDR) using the Benjamini–Hochberg method. The list
of genes associated with probes was derived from the annotation
provided by Illumina. The DNA methylation dataset is available
at the Gene Expression Omnibus (GEO) with accession number
GSE69229.
Quantitative DNA methylation analysis using
pyrosequencing
Genomic DNA (200 ng) was modified with sodium bisulfite
using the MethylampTM One-Step DNA Modification Kit (Epi-
gentek, Brooklyn, NY, USA) as per the manufacturer’s instruc-
tions. All samples were re-suspended in 15 ml of TE, and 1 ml of
this was used for subsequent PCR reactions. DNA samples were
amplified in 25 ml volumes containing 1X manufacturer’s buffer,
1 unit of FastStart Taq polymerase (Roche, Welwyn Garden
City, UK), 1–4 mM MgCl2, 10 mM dNTPs, and 75 ng of each
primer. PCR was performed for 40 cycles with an annealing tem-
perature of 53–63C, depending on the primer set being used.
For each set of primers (listed in Supplementary Table 3) one of
the forward or reverse primers included a 50 biotin label to allow
for subsequent analysis by pyrosequencing. Following PCR
amplification, sequencing was performed using a PSQ 96MA
pyrosequencer (Qiagen, Hilden, Germany), as per man-
ufacturer’s protocol. For all loci, assays were performed in dupli-
cate and values averaged between the duplicates. Only samples
that were passed by the pyrosequencer were included and to fur-
ther ensure a high degree of accuracy only runs in which single
peak heights were in excess of 200 were included. For CpG island
loci, between 3 and 6 consecutive CpG sites were measured and
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the methylation value for each locus was taken as the mean of all
CpG sites measured at that locus. For non CpG island associated
CpG sites, pyrosequencing assays were designed to include that
single specific CpG site. Primer design was performed using the
manufacturer’s provided PyroMark software and all pyrose-
quencing runs included in vitro methylated DNA (Millipore,
Watford, UK) and normal peripheral blood derived DNA as
control.
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